title: Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
abstract: Results of treatment for patients with non-Hodgkin's lymphomas have significantly improved over the last decade, especially following the discovery that anti-CD20 antibody therapy can significantly change the outlook for patients with both aggressive and indolent lymphomas. Although investigators have previously attempted to prevent relapses by intensifying chemotherapy programs for patients with poor-risk disease, further improvements in treatment will require development of biologic agents that can be added to current programs and exploitation of currently available drugs that can prevent recurrence of these diseases with good tolerability. This review analyzes currently available plans that can be used to maintain responses or "consolidate" initial responses to therapy, programs that may prevent relapse and potentially cure more patients with lymphomas, with a review of current ongoing trials designed along these lines.
authors.affiliation: Department of Lymphoma/Myeloma, M. D. Anderson Cancer Center, Houston, TX 77030, USA. fhagemei@mdanderson.org
authors.forename: Fredrick B
authors.initials: FB
authors.lastname: Hagemeister
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D019496:Cancer Vaccines / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D000068338:Everolimus; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007211:Indoles / Q000008:administration & dosage; D000077269:Lenalidomide; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000069283:Rituximab; D055502:Secondary Prevention; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives; D015996:Survival Rate / Q000639:trends; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019496:Cancer Vaccines; D007211:Indoles; D000069283:Rituximab; C422802:ibritumomab tiuxetan; D013792:Thalidomide; D000068338:Everolimus; D011505:Protein-Tyrosine Kinases; D000077269:Lenalidomide; C119496:tositumomab I-131; C504878:enzastaurin; D020123:Sirolimus
references.citation: Blood. 2005 Dec 1;106(12):3725-32
references.pmid: 16123223
references.citation: Oncogene. 2004 Apr 19;23(18):3151-71
references.pmid: 15094765
references.citation: Blood. 2008 Dec 15;112(13):4824-31
references.pmid: 18799723
references.citation: Cancer. 2008 Nov 15;113(10):2714-23
references.pmid: 18853418
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Clin Oncol. 1998 Aug;16(8):2825-33
references.pmid: 9704735
references.citation: Drugs. 2010 Feb 12;70(3):261-72
references.pmid: 20166765
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3918-28
references.pmid: 11579112
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):28-40
references.pmid: 15671525
references.citation: J Clin Oncol. 2007 May 1;25(13):1741-6
references.pmid: 17389337
references.citation: J Clin Oncol. 2005 Aug 10;23(23):5347-56
references.pmid: 15983389
references.citation: Leukemia. 2007 Feb;21(2):333-9
references.pmid: 17136116
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7565-73
references.pmid: 16186600
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5696-704
references.pmid: 16110029
references.citation: N Engl J Med. 2005 Feb 3;352(5):441-9
references.pmid: 15689582
references.citation: J Clin Oncol. 2005 Feb 1;23(4):712-9
references.pmid: 15613695
references.citation: Ann Oncol. 1998 Sep;9(9):995-1001
references.pmid: 9818074
references.citation: Br J Haematol. 2006 Sep;134(5):475-84
references.pmid: 16856892
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1088-95
references.pmid: 15657401
references.citation: J Clin Oncol. 2009 Apr 1;27(10):1607-14
references.pmid: 19255334
references.citation: J Clin Oncol. 2010 Oct 10;28(29):4480-4
references.pmid: 20697092
references.citation: Blood. 2003 Oct 1;102(7):2351-7
references.pmid: 12750161
references.citation: Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85
references.pmid: 16001955
references.citation: Cancer. 2010 Sep 15;116(18):4256-65
references.pmid: 20549832
references.citation: Cancer. 2008 Aug 1;113(3):508-14
references.pmid: 18543327
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5156-64
references.pmid: 18854568
references.citation: J Clin Oncol. 2002 May 15;20(10):2453-63
references.pmid: 12011122
references.citation: Cancer Biother Radiopharm. 2005 Apr;20(2):185-8
references.pmid: 15869453
references.citation: Cancer Biol Ther. 2003 May-Jun;2(3):222-32
references.pmid: 12878853
references.citation: Cancer. 2006 Feb 1;106(3):616-22
references.pmid: 16362977
references.citation: J Clin Oncol. 2002 Aug 1;20(15):3262-9
references.pmid: 12149300
references.citation: Blood. 2005 Feb 15;105(4):1417-23
references.pmid: 15494430
references.citation: Cancer Control. 2005 Apr;12(2):91-104
references.pmid: 15855892
references.citation: J Clin Oncol. 2007 May 20;25(15):1986-92
references.pmid: 17420513
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1096-102
references.pmid: 15657402
references.citation: J Clin Oncol. 2006 Sep 1;24(25):4143-9
references.pmid: 16896003
references.citation: J Clin Oncol. 2009 Jul 10;27(20):3346-53
references.pmid: 19451441
references.citation: J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301
references.pmid: 16985248
references.citation: Blood. 2008 Jun 15;111(12):5486-95
references.pmid: 18390837
references.citation: Haematologica. 2007 Jun;92(6):826-33
references.pmid: 17550856
references.citation: Blood. 2004 Nov 15;104(10):3064-71
references.pmid: 15284112
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3885-90
references.pmid: 12228209
references.citation: J Clin Oncol. 2010 Jun 10;28(17):2853-8
references.pmid: 20439641
references.citation: J Clin Oncol. 2008 Oct 20;26(30):4952-7
references.pmid: 18606983
references.citation: Blood. 2004 Jun 15;103(12):4416-23
references.pmid: 14976046